Treatment of androgen excess in females: Yesterday, today and tomorrow

Gynecological Endocrinology

Volumn 11, Issue 6, 1997, Pages 411-433

  Pucci, E ^a   Petraglia, F ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Androgen excess; Females; Hirsutism

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BROMOCRIPTINE; CYPROTERONE; DEXAMETHASONE; ESTROGEN; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROCORTISONE; ORAL CONTRACEPTIVE AGENT; SOMATOSTATIN DERIVATIVE;

ACNE; ADRENAL TUMOR; ALOPECIA; ANDROGEN RELEASE; DIFFERENTIAL DIAGNOSIS; DISTRESS SYNDROME; ETHNIC GROUP; FATIGUE; FEMALE; FEMININITY; GLUCOSE INTOLERANCE; GONADOTROPIN RELEASE; HEPATITIS; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERPLASIA; HYPERTENSION; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MUSCLE CONTRACTION; NAUSEA; OBESITY; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS; WEIGHT REDUCTION;

EID: 0031445050     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599709152569     Document Type: Review

References (277)

1. Montagna, W. and Scott, E. J. (1958). The anatomy of hair follicle. In Montagna, W. and Scott, E. J. The Biology of Hair Growth, pp. 39-64. (New York: Academic Press)
2. Hashimoto, K. (1988). The structure of human hair. Clin. Dermatol., 6, 7-21
3. Danforth, C. H. and Trotter, M. (1982). The distribution of body hair in white subjects. Am. J. Phys. Anthrop., 5, 259
4. Van Scott, E. H. (1964). Physiology of hair growth. Clin. Obstet. Gynecol., 7, 1062
5. Itami, S., Kurata, S., Sonoda, T. and Takayasu, S. (1991). Mechanism of action of androgens in dermal papilla cells. Ann. New York Acc. Sci., 642, 385-95
6. Saitoh, M. and Sakamoto, M. (1970). Human hair cycle. J. Invest. Dermatol., 54, 65-81
7. Tammi, R. and Santti, R. (1989). Morphometric analysis of human epidermis treated with testosterone and dehydroepiandrosterone in organ culture. Arch. Dermatol. Res., 281, 417
8. Leshin, M. and Wilson, J. (1981). Mechanism of androgen-mediated hair growth. In Orfomos, C. E., Montagna, W. and Stuttgen, G. (eds) Hair Research, pp. 205-9. (Berlin: Springer-Verlag)
9. Thornton, M. J., Messenger, A. G., Elliot, K. and Randall, V. A. (1991). Effects of androgens on the growth of cultured human dermal papilla cells derived from beard and scalp hair follicles. J. Invest. Dermatol., 97, 345-8
10. Bardin, W. C. and Lipsett, M. B. (1967). Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J. Clin. Invest., 46, 891-902
11. Serafini, P. and Lobo, R. A. (1972). Increased 5 α-reductase activity in idiopathic hirsutism. Fertil. Steril., 43, 74-9
12. Matteri, R. K., Stanczyk, F. Z., Gentzschein, E. E., Delgado, C. and Lobo, R. A. (198). Androgen sulfate and glucuronide conjugates in non-hirsute and hirsute women with polycystic ovarian syndrome. Am. J. Obstet. Gynecol., 161, 1704-9
13. Ebling, F. J. G., Hale, P. A. and Randall, V. A. (1991). Hormones and hair growth. In Goldsmith, L. A. (ed.) Biochemistry and Physiology of the Skin. (Oxford: Clarendon Press)
14. Hamilton, J. B. (1958). Age, sex and genetic factors in the regulation of hair growth in man: a comparison of Caucasian and Japanese populations. In Montagna, W. and Ellis, R. A. (eds) The Biology of Hair Growth, pp. 399-433. (New York: Academic Press)
15. Ferriman, D. and Gallwey, J. D. (1961). Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab., 21, 1440
16. McKnight, E. (1964). The prevalence of hirsutism in young women. Lancet, 1, 400
17. Lorenzo, E. M. (1970). Familial study of hirsutism. J. Clin. Endocrinol. Metab., 31, 556
18. Madanes, A. E. and Novotny, M. (1987). The vellus index: a new method of assessing hair growth. Fertil. Steril., 48, 1064
19. Ebling, F. J. G. and Randall, V. A. (1985). Hormonal action on hair follicles and associated glands. In Skerrow, D. and Skerrow, C. J. (eds) Methods in Skin Research, pp. 297-327. (New York: John Wiley)
20. Seago, S. V. and Ebling, F. J. G. (1985). The hair cycle on the human thigh and upper arm. Br. J. Dermatol., 113, 9-16
21. Greemblatt, R. B. and Gambrell, R. D. (1987). The ovary as a source of androgens A. The polycystic ovary B. Masculinising ovarian tumors. In Greemblatt, V. B., Mahesch, V. B. and Gambrell, R. D. (eds) The Cause and Management of Hirsutism, pp. 83-97. (Carnforth, UK: Parthenon Press)
22. Derogatis, L. R., Rose, L. I., Shulman, L. H. and Lazarus, L. A. (1993). Serum androgens and psychopathology in hirsute women. J. Psychosom. Obstet. Gynecol., 14, 269-82
23. Lobo, R., Granger, L., Goebelsmann, U. and Mishell, D. (1985). Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome. Am. J. Obstet. Gynecol., 15, 496-503
24. Chavis, W. M., La Ferla, J. J., Brown, J. C. and Keith, K. B. (1989). Psychosexual aspects of virilization syndrome. Int. J. Gynecol. Obstet., 30, 389-94
25. Faure, M. and Drapier-Faure, E. (1992). Hormonal assessment in a woman with acne and alopecia. Rev. Fr. Gynecol. Obstet., 87, 331-4
26. Jebraili, R., Kaur, S., Kanwar, A. J., Kataria, S. and Dash, R. J. (1994). Hormone profile and polycystic ovaries in acne vulgaris. Ind. J. Med. Res., 100, 73-6
27. Vewiau, P., Husson, C., Chivot, M., Brerault, J. L., Fiet, J., Julien, R., Villette, J. M., Hardy, N. and Cathelineau, G. (1990). Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J. Invest. Dermatol., 94, 279-83
28. Medda, F., Nieddu, R., Fiore, R., Marcello, C. and Lecca, U. (1988). Hormonal profile and androgen status during the menstrual cycle in women with acne. Clin. Exp. Obstet. Gynecol., XV, 137-42
29. De Raeve, L., De Shepper, J. and Smitz, J. (1995). Prepubertal acne: a cutaneous marker of androgen excess. J. Am. Acad. Dermatol., 32, 181-4
30. Rosenfield, R. L. and Lucky, A. W. (1993). Acne, hirsutism and alopecia in adolescent girls. Clinical expression of androgen excess. Endocrinol. Metab. Clin. N. Am., 22, 507-32
31. Braun-Falco, O., Plewig, G., Wolf, H. H. and Winkelman, R. K. (1988). Diseases of the sebaceous follicles. Dermatology, pp. 716-21. (Berlin: Springer-Verlag)
32. Redmond, G. P. and Bergfeld, W. F. (1990). Diagnostic approach to androgen disorders in women: acne, hirsutism and alopecia. Cleve. Clin. J. Med., 57, 423-7
33. Sheehan-Dare, R. A., Hughes, B. R. and Cunliffe, W. Y. (1988). Clinical markers of androgenicity in acne vulgaris. Br. J. Dermatol., 119, 723-30
34. Lucky, A. W. (1995). Hormonal correlates of acne and hirsutism. Am. J. Med., 16, 898-46
35. Levell, M. J., Cawood, M. L., Burke, B. and Cunliffe, W. J. (1989). Acne is not associated with abnormal plasma androgens. Br. J. Dermatol., 120, 649-54
36. Fiet, J., Gosling, J. P., Soliman, H., Galons, H., Boudou, P., Aubin, P., Belanger, A., Villette, J. M., Julien, R. and Brerault, J. L. (1994). Hirsutism and acne in women: coordinated radioimmunoassay for eight relevant plasma steroids. Clin. Chem., 40, 2296-305
37. Hamilton, J. B. (1951). Patterned loss of hair in man; types and incidence. Ann. N. Y. Acad. Sci., 53, 708-28
38. Norwood, O. T. (1975). Male pattern baldness: classification and incidence. South. Med. J., 68, 1359-65
39. Setty, L. R. (1970). Hair patterns of the scalp of white and negro males. Am. J. Phys. Anthropol., 33, 49-55
40. Randall, V. A. and Ebling, F. J. G. (1991). Seasonal changes in human hair growth. Br. J. Dermatol., 124, 146-51
41. Bradfield, R. B., Bailey, M. A. and Cordano, J. A. (1968). Hair-root changes in andean indian children during marasmic kwashiorkor. Lancet, II, 1169-70
42. Bradfield, R. B., Cordano, A. and Graham, G. G. (1969). Hair-root adaptation to marasmus in andean indian children. Lancet, II, 1395-7
43. Sims, R. T. (1967). Hair growth in kwashiorkor. Arch. Dis. Child., 42, 397-400
44. Bergfeld, W. F. (1995). Androgenic alopecia: an autosomal dominant disorder. Am. J. Med., 16, 958-88
45. Randall, V. A., Thornton, M. J. and Messenger, A. G. (1992). Cultured dermal papilla cells from androgen-dependent human follicles contain more androgen receptors than those from non-balding areas. J. Endocrinol., 133, 141-7
46. Orentrich, N. (1969). Scalp in hair replacement in man. In Montagna, W. and Dobson, R. L. (eds) Advances in Biology of Skin, vol. 9, Hair Growth, pp. 99-108. (London: Pergamon Press)
47. Ludwig, E. (1977). Classification of androgenic alopecia occurring in the female sex. Br. J. Dermatol., 97, 247-54
48. Eckert, J., Church, R. E., Ebling, F. J. and Munro, D. S. (1967). Hair loss in women. Br. J. Dermatol., 79, 543-8
49. Jakson, D., Church, R. E. and Ebling, F. J. (1972). Hair diameter in female baldness. Br. J. Dermatol., 87, 361-7
50. Zins, G. R. (1988). History of minoxidil. Clin. Dermatol., 6, 132-43
51. Roenigh, H. H. J. R., Pepper, E. and Kuruvilla, S. (1987). Topical minoxidil therapy for hereditary male pattern alopecia. Cutis, 39, 337-42
52. Baden, H. P., Grassi, A. and Kuedar, J. (1989). The effect of the drug minoxidil on hair growth. In Rogers, G. E., Reis, P. J., Ward, K. A., Marshall, R. C. (eds) The Biology of Wool and Hair, pp. 217-26. (London: Chapman & Hall)
53. Chang, F. J., Laufer, L. R., Meldrum, D. R., De Fazio, J., Lu, J. K., Vale, W. V., Rivier, J. E. and Judd, H. L. (1983). Steroid secretion in polycystic ovarian disease after ovarian suppression by a long acting gonadotropin releasing hormone agonist. J. Clin. Endocrinol. Metab., 56, 897-904
54. Andreyko, J. L., Monroe, S. E. and Jaffe, R. B. (1986). Treatment of hirsutism with gonadotropin releasing hormone agonist (naferalin). J. Clin. Endocrinol. Metab., 63, 854-9
55. Steingold, K., Ziegler, D. D., Cedars, M., Meldrum, D. R., Lu, J. K. and Judd, H. L. (1987). Clinical and hormonal effects of chronic gonadotropin releasing hormone agonist treatment in polycystic ovarian disease. J. Clin. Endocrinol. Metab., 65, 773-8
56. Rittmaster, R. (1988). Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin releasing hormone leuprolide. J. Clin. Endocrinol. Metab., 67, 651-5
57. Carmina, E., Stanczyk, F. Z., Gentzschein, E. and Lobo, R. A. (1995). Time dependent changes in serum 3-α androstanediol glucuronide correlate with hirsutism scores after ovarian suppression. Gynecol. Endocrinol., 9, 215-20
58. Adashi, E. Y. (1990). Potential utility of gonadotropin releasing hormone agonists in the management of ovarian hyperandrogenism. Fertil. Steril., 53, 765-79
59. Karten, M. J. and Rivier, J. E. (1986). Gonadotropin releasing hormone analog design: structure-function studies toward the development of agonists and antagonists. Endocr. Rev., 7, 44-59
60. Clayton, R. N. (1987). GnRH from physiology to pharmacology. Clin. Endocrinol., 26, 361-84
61. Rabin, D. and McNeil, L. W. (1980). Pituitary and gonadal desensitization after continuous luteinizing hormone-releasing hormone infusion in normal females. J. Clin. Endocrinol. Metab., 51, 873
62. Falsetti, L. and Pasinetti, E. (1994). Treatment of moderate and severe hirsutism by gonadotropin releasing hormone agonists in women with polycystic ovary syndrome and idiopathic hirsutism. Fertil. Steril., 61, 817-22
63. Carmina, E. and Lobo, R. A. (1995). GnRH-agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission, Fertil. Steril., Suppl. (Abstracts of the 41st Meeting of Reproductive Medicine, Seattle, October 7-12, 1995), abstr. 0.084, 102
64. De Fazio, J., Meldrum, D. R., Laufer, Vale, W. V., Rivier, J. E. and Lu, J. K. H. (1983). Induction of hot flashes in menopausal women treated with a long acting GnRH-agonist. J. Clin. Endocrinol., 35, 342-6
65. Carmina, E., Janni, A. and Lobo, R. A. (1994). Physiological estrogen replacement may enhance the effectiveness of the gonadotropin releasing hormone agonist in the treatment of hirsutism. J. Clin. Endocrinol. Metab., 78, 126-30
66. Lindsay, R., Hart, D. M. and Clark, D. M. (1984). The minimum effective dose of estrogen for prevention of post-menopausal bone loss. Obstet. Gynecol., 63, 759-63
67. Elkind-Hirsch, K. E., Anania, C., Mack, M. and Malina, K. R. (1995). Combination gonadotropin releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism. Fertil. Steril., 63, 970-8
68. Morcos, R. N., Abdul-Malak, M. E., Shikora, E. et al. (1994). Treatment of hirsutism with a gonadotropin releasing hormone agonist with and estrogen replacement therapy. Fertil. Steril., 61, 427-31
69. Lemay, A. and Faure, N. (1994). Sequential estrogen-progestin addiction to gonadotropin releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J. Clin. Endocrinol. Metab., 79, 1716-22
70. Steingold, K., Judd, H., Nieberg, R., Lu, J. and Chang, J. (1986). Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am. J. Obstet. Gynecol., 154, 1241-7
71. Rivier, J. (1993). Novel antagonists of GnRH: a compendium of their physiochemical properties, activities, relative potencies and efficacy in humans. In Lunenfeld, B. and Insler, V. (eds) GnRH Analogues. The State of the Art, pp. 13-26. (London: Parthenon Publishing Group)
72. Bokser, L., Bajusz, S., Groot, K. and Schally, A. V. (1990). Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl Acad. Sci. USA, 87, 7100-4
73. Diedrich, K., Diedrich, C., Santos, E., Zoll, C., Al Hasani, S., Reissmann, T., Krebs, D. and Klingmuller, D. (1994). Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian simulation. Hum. Reprod., 9, 788-91
74. Schmidt, F., Sundaram, K., Thau, R. B. and Bardin, C. W. (1984) (Ac-D-Nal (2) 1, 4FD-Phe2, D-TRP3, D-Arg6)-LH-RH, a potent antagonist of LH-RH, produces transient edema and behavioral changes in rats. Contraception, 29, 283-9
75. Hahn, D. W., McGuire, J. L., Vale, W. W. and Rivier, J. (1985). Reproductive endocrine and anaphylactoid properties of an LH-RH-antagonist, ORF-18260 (Ac-DNall (2), 4FDPhe2, D-TRP3, D-Arg6)-GnRH. Life Sci., 37, 505-14
76. Rivier, J. E., Porter, J., Rivier, C. L., Perrin, M., Corrigan, A. and Hook, W. A. (1986). New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J. Med. Chem., 29, 1846-51
77. Nestor, Jr J. J., Tahilramani, R., Ho, T. I., Goodpasture, J. C., Vickery, B. H. and Ferrnadon, P. (1988). Design of luteinizing hormone-releasing hormone peptides: Proceedings of the 20th European Peptide Symposium. Berlin: de Cruyter, 592-4
78. Gonzales-Barcena, D., Vadillo-Buenfil, M., Garcia-Procel, E., Mares, G., Bajusz, S. and Comaru-Schally, A. M. (1989). Inhibition of LH and FSH release in hypergonadotropic patients with new potent antagonists of LHRH free of anaphylactoid reactions. Endocrine Society Annual Meeting, Seattle, Washington, 21-24 June, Abstract 1712, p. 450
79. Bajusz, S., Kovacs, M., Gazdag, M., Bokser, L., Karashima, T., Csernus, V. J., Janaky, T., Guoth, J. and Schally, A. V. (1988). Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc. Natl Acad. Sci. USA, 85, 1637-41
80. Olivennes, F., Fanchin, R., Bouchard, P., De Ziegler, D., Taieb, J., Selva, J. and Frydman, R. (1994). The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril., 62, 468-76
81. Rabinovici, J., Rothman, P., Monroe, S. E., Neremberg, C. A. and Jaffe, P. (1992). Endocrine effects and pharmacokinetic characteristics of a potent new GnRH antagonist (Ganirelix) with minimal histamine-releasing properties: studies in post-menopausal women. J. Clin. Endocrinol. Metab., 75, 1220-5
82. Ljunqvist, A., Feng, D., Tang, P. F. L., Kubota, M., Okamoto, T., Hook, W. A. and Folkers, B. (1987). Design, synthesis and bioassays of antagonist of LHRH which have high antiovulary activity and release negligible histamine. Biochem. Biophys. Res. Commun., 148, 849-56
83. Barcena, D. G., Buenfil, Emilo, M. V., Procel, G., Arguero, L. G., Comejo, I. G., Comaru-Shally, A. L. and Shally, A. V. (1994). Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorilex (SB-75). Eur. J. Endocrinol., 131, 286-92
84. Gambrell, R. D. (1976). Regression of polycystic ovaries by estrogen therapy. Obstet. Gynecol., 47, 569
85. Casey, J. H., Burgher, H. G., Kent, J. R., Kellie, A. E., Moxham, A., Nabarro, J. and Nabarro, J. D. N. (1966). Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab., 26, 1370-4
86. Levrant, S. G. and Barnes, R. B. (1994). Pharmacology of estrogens. In Lobo, R. A. (eds) Treatment of Post-Menopausal Women, pp. 57-68. (New York: Raven Press)
87. Iperplasia Kurman, R. J., Kaminsky, P. T. and Norris, H. J. (1985). The behaviour of endometrial hyperplasia: a long-term study of untreated hyperplasia in 170 patients. Cancer, 56, 403-12
88. Huang, S. J., Amparo, E. G. and Fu, J. S. (1988). Endometrial hyperplasia: histological classification and behavior. Surg. Pathol., 1, 215-29
89. Ormann, O., Catt, K. J., Schulz, K. D. and Emons, G. (1994). Modulatory action of progesterone and progesterone antagonist on hypothalamic-pituitary function. Hum. Reprod., 9, 53-62
90. Wambach, G., Higgins, J. R., Kem, D. C. and Kaufmann, W. (1979). Interaction of synthetic progestagens with renal mineralo-corticoid receptors. Acta Endocrinol., 92, 560-7
91. Landau, R. L. and Lugibihl, K. (1958). Inhibition of the sodium retaining influence of aldosterone by progesterone. J. Clin. Endocrinol. Metab., 18, 1237-45
92. Losert, W., Casals-Stenzel, J. and Buse, M. (1985). Progestogens with antimineralocorticoid activity. Arzneimittelforschung, 35, 459-71
93. Krattenmacher, R. and Fromm, M. (1992). Mineralocorticid and antimineralocorticoid effects of various progestogens on electrogenic Na+ transport in the rat distal colon in vitro. Acta Endocrinol., 126, 88
94. Neumann, F. (968). Chemische Konstitution und pharmakologische Wirkung. In Junkmann, K. (ed.) Handbook of Exp. Pharmacology, Vol. 23, Part I: Die Gestagene, pp. 680-1025. (Berlin, Heidelberg, New York: Springer-Verlag)
95. Landau, R. L., Bergenstal, D. M., Lugibihl, K. and Kascht, M. E. (1955). The metabolic effects of progesterone in man. J. Clin. Endocrinol. Metab., 15, 1194-215
96. Landau, R. L. and Lugibihl, K. (1961). The catabolic and nutriuretic effects of progesterone in man. Recent. Progr. Horm. Res., 17, 249-92
97. Elger, W. and Beier, S. (1982). Überlegungen zur Bedeutung unterschiedlicher hormonaler Wirkungsspektren von Gestagenen. In Hammerstein, J. (ed.) Aktuelle Aspekte der hormonalen Kontrazeption. Excepta Med., 4.36, 9-27
98. Dorfman, R. I. (1963). Antiandrogens in a cast-rated mouse test. Steroids, 2, 185-93
99. Ettinger, B. and Golditch, I. M. (1977). Medroxyprogesterone acetate for the evaluation of hypertestosteronism in hirsute women. Fertil. Steril., 28, 1285-90
100. Gordon, G. G., Southern, A. L. and Calanog, A. (1972). The effect of medroxyprogesterone acetate on androgen metabolism in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 35, 444-9
101. Bazin, B., Thenevot, R., Bursaux, C. and Paris, J. (1987). Effects of nomegestrole-acetate, a new 19-nor-progesterone derivate, on pituitary-ovarian function in women. Br. J. Obstet. Gynaecol., 94, 1199-24
102. Botella, J. (1986). Interaction of a new 19-nor-progesterone derivative with progestagen mineralcorticoid receptors. J. Pharmacol., 17, 698-701
103. Botella, J. (1987). The cellular mechanism of the antiandrogenic action of nomegestrol acetate a new 19-nor-progesterone on the rat prostate. Acta Endocrinol., 115, 544-8
104. Oelkers, W., Berger, V., Bolik, A. et al. (1991). Dihydrospirorenone, a new progestogen with antimineralcorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J. Clin. Endocrinol. Metab., 73, 837-42
105. Muhn, P., Krattenmacher, R., Beier, S., Elger, W. and Schillinger, E. (1995). Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Contraception, 51, 99-110
106. Lemay, A., Dewailly, S. D., Granier, R. and Huard, J. (1990). Attenuation of mild hyper-androgenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J. Clin. Endocrinol. Metab., 71, 8-14
107. Robinson, G. E., Bounds, W., Mackie, I. J., Stocks, J., Machin, S. J. and Guillebaud, J. (1990). Changes in metabolism induced by oral contraceptives containing desogestrel in older women. Contraception, 42, 263-73
108. Givens, J. R., Andersen, R. N., Wiser, W. L. and Fish, S. A. (1974). Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive. J. Clin. Endocrinol. Metab., 38, 727
109. Raj, S. G., Raj, M. H. G., Talbert, L. M., Sloan, C. S. and Hicks, B. (1982). Normalization of testosterone levels using a low-dose estrogen containing oral contraceptive in women with polycystic ovary syndrome. Obstet. Gynecol., 60, 15-19
110. Wild, R. A., Umstot, E. S., Andersen, R. R. and Givens, G. R. (1982). Adrenal function in hirsutism: effect of an oral contraceptive. J. Clin. Endocrinol. Metab., 54, 676-81
111. Dewis, P., Petsos, P., Newman, M. and Anderson, D. C. (1985). The treatment of hirsutism with a combination of desogestrel and ethinyl-estradiol. Clin. Endocrinol., 22, 29-36
112. Pugeat, M. M., Dunn, J. F. and Nisula, B. C. (1981). Transport of steroid hormones: interaction of 70 drugs with testosterone binding globulin and corticosteroid binding globulin. J. Clin. Endocrinol. Metab., 53, 69-75
113. Drugs and Therapeutics Bulletin (1992). Starting oral contraceptives: which, when and how? Drugs Ther. Bull., 30, 41-4
114. Porcile, A. and Gallardo, E. (1991). Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives. Fertil. Steril., 55, 877-81
115. Karpas, A. E. (1987). The adrenal as source of androgens. In Greemblatt, R. B., Mahesh, V. B. and Gambrell, R. D. (eds) The Course and Management of Hirsutism, pp. 99-115. (Carnforth: Parthenon Publishing)
116. Abraham, G. E., Maroulis, G. B., Boyers, S. P., Buster, J. E., Magyar, G. M. and Elner, C. W. (1981). Dexamethasone suppression test in the management of hyperandrogenized patients. Obstet. Gynecol., 57, 158-65
117. Casey, J. H., Burger, H. D., Kent, J. R., Kellie, A. E., Moxham, A., Nabarro, J. and Nabarro, J. D. N. (1966). Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab., 26, 1370-4
118. Redmond, G. P., Gidwani, G. P., Gupta, M. K., Bedcos, N. M., Parker, R., Skibanski, C. and Bergfield, W. (1990). Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. J. Am. Acad. Dermatol., 22, 91-3
119. Spritzer, P., Billaund, L., Thalabard, J. K., Birman, P., Mowszowicz, I., Raux-Demay, M. C., Clair, F., Kutten, F. and Mauvais-Jarvis, P. (1990). Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia. J. Clin. Endocrinol. Metab., 70, 642-6
120. Casey, J. K., Burgher, H. G., Kent, J. R. and Kellie, A. E. (1966). Treatment of hirsutism by adrenal and ovarian suppression. J. Clin. Endocrinol. Metab., 26, 1370
121. Girard, J., Baumann, J. B., Buhler, U., Zuppinger, K., Haas, H. G., Staubb, J. J. and Wiss, H. I. (1978). Cyproterone and ACTH adrenal function. J. Clin. Endocrinol. Metab., 47, 581-5
122. Jeffcoate, W. J., Rees, L. H., Edwards, C. R. W. and Besser, G. M. (1976). Cyproterone acetate and its effect on ACTH secretion. Lancet, 1, 1140-2
123. Girard, J., Baumann, J. B., Bohler, U., Zuppinger, K., Haas, H. G., Staub, J. J. and Wyss, H. I. (1978). Cyproterone acetate and ACTH adrenal function. J. Clin. Endocrinol. Metab., 47, 581-5
124. Higuchi, K., Nawata, H., Maki, T., Hagashizima, M., Kato, K. I. and Ibayashi, H. (1984). Prolactin has a direct effect on adrenal androgen secretion. J. Clin. Endocrinol. Metab., 59, 714-18
125. Serafini, P. and Lobo, R. A. (1986). Prolactin modulates peripheral androgen metabolism. Fertil. Steril., 45, 41-4
126. Ho, K. Y. and Thorner, M. O. (1988). Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs, 36, 67-82
127. Crosignani, P. G. and Ferrari, C. (1990). Dopaminergic treatments for hyperprolactinaemia. Bailliere's Clin. Obstet. Gynecol., 4, 441-55
128. Vance, M. L., Evans, W. S. and Thorner, M. O. (1984). Drugs five years later: bromocriptine. Ann. Int. Med., 100, 78-91
129. Van der Heijden, P. F. M., de Wit, W., Brownell, J., Shoemaker, J. and Rolland, R. (1991). CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur. J. Obstet. Gynecol. Reprod. Biol., 40, 111-18
130. Webster, J., Pisatelli, G., Polli, A., Ferrari, C. I., Ismail, I. and Scanlon, M. F. (1994). A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med., 331, 904-9
131. Ferrari, C., Paracchi, A., Mattei, A. M., de Vincentiis, S., D'Alberton, A. and Crosignani, P. G. (1992). Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh)., 126, 489-94
132. Sawers, R. A., Randall, V. A. and Iqbal, M. J. (1982). Studies on the clinical and endocrine aspects of antiandrogens. In Jeffcoate, S. L. (ed.) Androgens and Antiandrogens Therapy. Current Topics in Endocrinology, Vol. 1, pp. 145-68. (Chichester: John Wiley)
133. Neumann, F., Graf, K. J., Hasan, S. H., Schench, B. and Steimbeck, H. (1977). Central action of antiandrogens. In Martini, L. and Motta, M. (eds) Androgens and Antiandrogens, pp. 163-77. (New York: Raven Press)
134. Dorfman, R. I. (1970). Biological activity of antiandrogens. Br. J. Dermatol., 82, 3-8
135. Hammerstein, J. and Cupceancu, B. (1969). Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch. Med. Wochenschr., 94, 829-34
136. Hammerstein, J., Meckies, J., Leo-Rossberg, I., Moltz, L. and Zielske, I. (1975). Use of cyproterone acetate in the treatment of acne, hirsutism and virilism. J. Steroid Biochem., 6, 827-36
137. Hammerstein, J. and Cupceancu, B. (1969). The treatment of hirsutism with cyproterone acetate. Germ. Med. Monthly, 14, 599-602
138. Mowszowicz, I., Raihi, M. and Wright, M. (1981). Androgen receptors in human skin cytosol. J. Clin. Endocrinol. Metab., 52, 338-44
139. Neumann, F. and Schleusener, A. (1980). Pharmacology of cyproterone acetate with special reference to the skin. In Vokaer, N. and Fanta, D. (eds) Proceedings of the Diane symposium, pp. 19-51. (Brussels, Amsterdam: Excerpta Medica)
140. Mowsowicz, I., Wright, F. and Vincens, M. (1984). Androgen metabolism in hirsute females treated with cyproterone acetate. J. Steroid Biochem., 20, 757-61
141. Kutten, F., Mowsowicz, I. and Mauvais-Jarvis, P. (1980). Androgen metabolism in human skin. In Mauvais-Jarvis, P., Vickers, C. and Wepierre, J. (eds) Percutaneous Absorption of Steroids, pp. 99-121. (London: Academic Press)
142. Jasonni, V. M., Di Cosmo, E., Bulletti, C., Cappuccini, P., Naldi, S. and Flamigni, C. (1991). Treatment of hirsutism by an association of oral cyproterone acetate and transdermal β-estradiol. Fertil. Steril., 55, 742-5
143. Schmidt, J. B., Hber, J. and Spona, J. (1987). Parenteral and oral cyproterone acetate treatment in severe hirsutism. Gynaecol. Obstet. Invest., 24, 125-30
144. Marcondes, A. M., Wajchemberg, B. L., Abujamra, A. C., Luthold, W. W., Samojlik, E. and Kirschner, M. A. (1990). Monthly cyproterone acetate in the treatment of hirsute women: clinical and laboratory effects. Fertil. Steril., 53, 40-4
145. Belisle, S. and Love, E. G. (1986). Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of multicenter Canadian study. Fertil. Steril., 46, 115-20
146. Barth, J. H., Cherry, C. A., Wojnarowska, F. and Dawber, R. P. R. (1991). Cyproterone acetate for severe hirsutism: results of a double blind dose-ranging study. Clin. Endocrinol., 35, 5-10
147. Holdaway, I. M., Croxsom, M. S. and Ibbotson, H. K. (1985). Cyproterone acetate as initial treatment and maintenance therapy for hirsutism. Acta Endocrinol., 109, 522-9
148. Porcile, A. and Gallardo, E. (1991). Oral contraceptives containing desogestrel in the maintenance of the remission of hirsutism: monthly versus bimonthly treatment. Contraception, 44, 533-9
149. Seed, M., Godsland, I. F., Wynn, V. and Jacobs, H. S. (1984). The effects of cyproterone acetate and ethinyl oestradiol on carbohydrate metabolism. J. Clin. Endocrinol. Metab., 51, 231-6
150. Vermeulen, A. and Rubens, R. (1990). Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraceptive, 28, 167-71
151. Noguchi, S., Nishizama, J. and Uchida, N. (1985). Stimulatory effect of physiological doses of androgens or pharmacological doses of estrogens on growth of Shinogi carcinoma 115 in mice. Cancer Res., 45, 546-60
152. Luthy, L. A., Bégin, D. J. and Labrie, F. (1988). Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shinogi) cells in culture. J. Steroid Biochem., 31, 845-52
153. Plante, M., Lapointe, S. and Labrie, F. (1988). Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shinogi tumor in mice. J. Steroid Biochem., 52, 338-44
154. Labrié, C., Cusan, L. and Plante, M. (1987). Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28, 379-84
155. Bressollette, L., Dubois, A., Carlhant, D., Morand, C., Mottier, D. and Riche, C. (1994). Fatal hepatitis caused by cyproterone acetate. Therapie, 49, 153-5
156. Hirsch, D., Kovatz, S., Bernheim, J. and Shenkman, L. (1994). Fatal fulminant hepatitis from cyproterone acetate. Isr. J. Med. Sci., 30, 238-40
157. Roila, F., Crino, L., Carloni, G. and Natalini, G. (1993). Cyproterone acetate: hepatoxicity and prostatic cancer treatment. Ann. Oncol., 4, 701-4
158. Gerlyng, P., Grotmol, T. and Seglen, P. O. (1994). Effect of 4-acetylaminofluorence and other tumor promoter on hepatocellular growth and binucleation. Carcinogenesis, 15, 371-9
159. Kattan, J., Spatz, A., Culine, S., Terrier-Lacombe, M. J., Elias, D. and Droz, J. P. (1994). Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am. J. Clin. Oncol., 17, 390-2
160. Roberts, R. A., Soames, A. R., Gill, J. H., James, N. H. and Wheeldon, E. B. (1994). Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induced apoptosis, but in different hepatocyte populations. Carcinogenesis, 16, 1693-8
161. Topinka, J., Binkowa, B., Zhu, H. K., Andrae, U., Neumann, I., Schwarz, L. R., Werner, S. and Wolff, T. (1995). DNA-damaging activity of the cyproterone acetate analogues chlormadinone acetate and megestrol acetate in rat liver. Carcinogenesis, 16, 1483-7
162. Rudiger, T., Beckmann, J. and Queisser, W. (1995). Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyl-oestradiol. Lancet, 18, 452-3
163. Hammerstein, J., Rabe, T. and Runnebaum, B. (1995). Position of the German Society of Gynecology and Obstetrics on the intended recall of approved CPA-containing drugs. Gynäkol. Geburtshilfliche Rundsch., 35, 49-50
164. Corvol, P., Michaud, A. and Menard, J. (1975). Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology, 46, 1015-20
165. Eil, C. and Edelsen, S. K. (1984). The use of skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab., 59, 51-5
166. Stripp, B., Taylor, A. A. and Bartter, F. C. (1975). Effect of spironolactone on sex hormones in man. J. Clin. Endocrinol. Metab., 41, 777-81
167. Evans, D. J. and Burke, C. W. (1986). Spironolactone in the treatment of idiopathic hirsutism and polycystic ovary syndrome. J. R. Soc. Med., 79, 451-3
168. Young, R. L., Goldzieher, J. W. and Eckland-Hirsh, K. (1987). The endocrine effects of spironolactone as an anti-androgen. Fertil. Steril., 48, 223-8
169. Menard, R. H., Guenther, T. M., Kol, H. and Gillette, G. R. (1979). Studies on the destruction of adrenal and testicular cytochrome P-450 by spironolactone. J. Biol. Chem., 254, 1726-33
170. Rose, L. I., Underwood, L. H. and Newmark, S. R. (1977). Pathophysiology of spironolactone-induced gynecomastia. Ann. Int. Med., 87, 397-403
171. Cumming, D. C., Yang, G. C., Rebar, R. W. and Yen, S. S. C. (1982). Treatment of hirsutism with spironolactone. JAMA, 247, 1295
172. Evron, S., Shapiro, G. and Diamant, Y. Z. (1981). Induction of ovulation with spironolactone (aldactone) in anovulatory, oligomenorrheic women. Fertil. Steril., 36, 468-72
173. Ylostalo, P., Heikkinen, J., Kauppila, A., Pakarinen, A. and Jarvinen, P. A. (1987). Low-dose spironolactone in the treatment of female hirsutism. Int. Fertil., 32, 41-5
174. Lobo, R. A., Shoupe, D., Serafini, P., Brinton, D. and Horton, R. (1985). The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil. Steril., 43, 200-5
175. Callan, A. W. (1988). Spironolactone therapy in hirsutism and acne. Aust. J. Dermatol., 29, 135-9
176. McLellan, A. R., Rentoul, J., Mackie, R. and McInnes, G. T. (1989). Lack of effect of spironolactone on hair shaft diameter in hirsute females. Postgrad. Med. J., 65, 459-62
177. Renkes, P., Gaucger, P. and Trechot, P. (1995). Spironolactone and hepatic toxicity. JAMA, 273, 376-7
178. Zapater, P. and Albba, D. (1995). Acidosis and extreme hyperkalemia associated with cholestyramine and spironolactone. Ann. Pharmacother., 29, 199-200
179. Wild, R. A., Demers, L. M., Applebaum-Bowden, D. and Lenker, R. (1991). Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception, 44, 113-24
180. Berardesca, E., Gabba, P., Ucci, G., Borroni, G. and Rabbiosi, G. (1988). Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int. J. Reac., X, 115-19
181. Funder, J. W. and Mercer, J. E. (1979). Cimetidine, a histamine H2 receptor antagonist, occupies androgen receptors. J. Clin. Endocrinol. Metab., 48, 189-91
182. Vigersky, R. A., Mehlman, I., Glass, A. R. and Smith, S. E. (1980). Treatment of hirsute women with cimetidine. N. Engl. J. Med., 303, 1042-6
183. Lissak, A., Sorpkin, Y., Calderon, I., Dirnfield, M., Lioz, H. and Abramovici, H. (1989). Treatment of hirsutism with cimetidine; a prospective randomized trial. Fertil. Steril., 51, 247
184. Eu, C. and Edelson, S. K. (1984). The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors. J. Clin. Endocrinol. Metab., 59, 51-5
185. Heel, R. C., Brogden, R. N., Carmine, A., Morley, P. A., Speigh, T. M. and Avery, G. S. (1982). Ketoconazole: a review of its therapeutical efficacy in
186. Pont, A., Williams, P. L. and Azhar, S. (1982). Ketoconazole blocks testosterone synthesis. Arch Int. Med., 142, 2137
187. Feldmann, D. (1986). Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev., 7, 409
188. Santen, R. J., Van den Bossche, H., Symoens, J., Brugmans, J. and De Coster, R. (1983). Site of action of low dose ketoconazole on androgen biosynthesis in men. J. Endocrinol. Metab., 57, 732-6
189. Lamberts, S. W. J., Bons, E. G., Bruining, H. A. and dejong, F. H. (1987). Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J. Pharmacol. Exp., 240, 259
190. McCance, D. R., Hadden, D. R., Kenne, Y. L., Sheridan, B. and Atkinson, A. B. (1987). Clinical experience with ketoconazole as therapy for patients with Cushing's syndrome. Clin. Endocrinol., 27, 593
191. Boscaro, N., Sonino, M., Rampazzo, A. and Mantero, F. (1987). Response of pituitary-adrenal axis to corticotropin releasing-hormone in patients with Cushing's disease before and after ketoconazole treatment. Clin. Endocrinol., 27, 461
192. Loli, P., Berselli, M. E. and Tagliaferri, M. (1986). Use of ketoconazole in the treatment of Cushing's syndrome. J. Clin. Endocrinol. Metab., 63, 1365
193. Sonino, N. (1988). Current trends in the endocrine use of ketoconazole. J. Endocrinol. Invest., 11, 741
194. Conget, J. I., Halperin, I., Ferrer, J., Gonzales-Clemente, J. M., Martinez-Osabam, M. J. and Vilardell, E. (1990). Evaluation of clinical and hormonal effects in hirsute women treated with ketoconazole. J. Endocrinol. Invest., 13, 867-70
195. Carvalho, D., Pignatelli, D. and Resende, C. (1985). Ketoconazole for hirsutism. Lancet, II, 560
196. Akalin, S. (1991). Effects of ketoconazole in hirsute women. Acta Endocrinol. (Copenh.), 124, 19-22
197. Martikainen, J., Heikkinen, J., Ruokonen, A. and Kauppilia, A. (1988). Hormonal and clinical effects of ketoconazole in hirsute women. J. Endocrinol. Metab., 66, 987-91
198. Lewis, J. H., Zimmermann, H. J., Benson, G. D. and Ishak, K. G. (1984). Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology, 86, 503-13
199. Lake-Bakaar, G., Scheuer, S. and Sherlok, S. (1987). Hepatic reactions associated with ketoconazole in the United Kingdom. Br. Med. J., 294, 419-22
200. Mecnair, A. L., Gascoigne, E., Heap, J., Schuermans, V. and Symoens, J. (1981). Hepatitis and ketoconazole therapy. Br. Med. J., 283, 1058
201. Peter, R. U. and Richarz-Barthauer, U. (1995). Successful treatment and prophylaxis of scalp seborrheic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br. J. Dermatol., 132, 441-5
202. Neri, U., Bartalucci, S., Pieri, A., Gemelli, M. T., Rizzo, M., Bartoletti, K., Trippitelli, A. and Paoletti, M. C. (1989). Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects. Anticancer Res., 9, 13
203. Neri, R. and Kassem, N. (1984). Biological and clinical properties of antiandrogens. In Bresciani, A. (ed.) Progress in Cancer Research and Therapy, vol. 31. (New York: Raven Press)
204. Teutsch, G., Goubet, F., Battmann, T., Bonfils, A., Bochoux, F., Cerede, E., Gofflo, D., Gaillard-Kelly, T. and Philibert, D. (1994). Non-steroidal antiandrogens: synthesis and biological profile of high affinity ligands for the androgen receptor. J. Steroid Biochem., 48, 111-19
205. Peets, E. A., Henson, M. F. and Neri, R. (1974). On the mechanism of the anti-androgenic action of flutamide (α-α-α-trifluoro-2-methyl-nitro-m-propionotoluidide) in the rat. Endocrinology, 94, 532-40
206. Liao, S., Kohowell, D. and Chang, T. M. (1974). Action of nonsteroidal antiandrogen flutamide on the receptor binding and nuclear retention of 5-α-dihydro-testosterone in rat ventral prostate. Endocrinology, 94, 1205
207. Irwin, R. J. and Prout, G. R. (1976). A new antiprostatic agent for treatment of prostatic carcinoma. Surg. Forum, 24, 536-8
208. Daricello, G., Serretta, V. and Pavone-Macaluso, M. (1987). Flutamide in the treatment of advanced prostatic cancer. J. Drug Dev., 1, 17-22
209. Sogani, P. C., Vagaiwala, M. R. and Whitmore, W. F. (1984). Experience with flutamide in patients with advanced prostatic carcinoma without prior endocrine therapy. Cancer, 54, 744-50
210. Couzinet, B., Pholsena, M., Young, J. and Schaison, G. (1993). The impact of a pure antiandrogen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin. Endocrinol., 39, 157-62
211. Marcondes, J. A. M., Minnani, L. S., Luthold, W. W., Wajchemberg, B. L., Samojlik, E. S. and Kirschner, M. A. (1992). Treatment of hirsutism in women with flutamide. Fertil. Steril., 57, 543-7
212. Cusan, L., Dupont, A., Bélanger, A., Tremblay, R., Manhes, G. and Labrie, F. (1990). Treatment of hirsutism with the pure antiandrogen flutamide. J. Am. Acc. Dermatol., 23, 462-9
213. Presl, J. (1994). Therapy of hirsutism with flutamide, a new non-steroidal antiandrogen. Ceska. Gynekol., 59, 275-6
214. Motta, T., Maggi, G., Perra, M., Azzolari, E., Casazza, S. and D'Alberton, A. (1991). Flutamide in the treatment of hirsutism. Int. J. Gynecol. Obstet., 36, 155-7
215. Pucci, E., Genazzani, A. D., Monzani, F., Lippi, F., Angelini, F., Gargani, M., Barletta, D., Luisi, M. and Genazzani, A. R. (1995). Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol. Endocrinol., 9, 221-8
216. Marugo, M., Bernasconi, D., Meozzi, M., Del Monte, P., Zino, V., Primarolo, P. and Bardaracco, B. (1994). The use of flutamide in the management of hirsutism. J. Endocrinol. Invest., 17, 195-9
217. Balzano, S., Cappa, M., Migliari, R., Scarpa, R. M., Danielli, E., Campus, G., Pintus, C., Sica, V. and Martino, M. (1988). The effects of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer. J. Endocrinol. Invest., 11, 693-6
218. Hellmann, L., Bradlow, H. L., Freed, S., Levin, J., Rosenfeld, R. S., Withmore, W. F. and Zumoff, B. (1977). The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J. Clin. Endocrinol. Metab., 45, 1224-9
219. Matzger, D. L. and Kerrigan, J. R. (1993). Androgen receptor blockade with flutamide enhances growth hormone secretion in late pubertal males: evidence for independent actions of estrogen and androgen. J. Clin. Endocrinol. Metab., 76, 1147-52
220. Wysowsky, D. K. and Fourcroy, J. L. (1996). Flutamide hepatotoxicity. J. Urol., 155, 226-7
221. Kosar, J., Sasmaz, N., Oguz, P. and Kucukbas, S. (1995). Hepatic insufficiency developing as a result of flutamide treatment. Am. J. Gastroenterol., 90, 1027-8
222. Poyet, P. and Labié, F. (1985). Comparison of antiandrogen/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42, 238-8
223. Knuth, U. A., Hano, R. and Nieschlag, E. (1984). Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J. Clin. Endocrinol. Metab., 59, 963-8
224. Eremus, M. (1993). Efficacy of flutamide versus spironolactone. Fertil. Steril., 63, 680
225. Eremus, M., Garbuz, O., Durmusoglu, F., Demirkay, Z. and Pekin, S. (1994). Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil. Steril., 61, 613-16
226. Eri, L. M. and Tveter, K. J. (1993). A prospective, placebo controlled study of the antiandrogen casodex as treatment for patients with benign prostatic hyperplasia. Br. J. Urol., 150, 90-4
227. Eri, L. M. and Haug, E. (1995). Effects on endocrine system of long-term treatment with non-steroidal anti-androgen casodex in patients with benign prostate hyperplasia. Br. J. Urol., 75, 335-40
228. Teutsch, G., Goubet, F., Battmann, T., Bonfils, A., Bouchoux, F., Cerede, E., Gofflo, D., Gaillard-Kelly, M. and Philibert, D. (1994). Non steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J. Steroid. Biochem. Mol. Biol., 48, 11-19
229. Chan, H. C., Geissler, W. M. and Anderson, S. (1994). Characterization of human steroid 5α-reductase types I and II expressed in the baculovirus system. In Motta, M. and Serio, M. (eds) Sex Hormone and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects, pp. 67-76. (Amsterdam: Elsevier Science B. V.)
230. Gilad, S., Chayen, R., Tordjman, K., Kisch, E. and Stern, N. (1994). Assessment of 5 alpha-reductase activity in hirsute women: comparison of serum androstanediol glucuronide with urinary androsterone and aetiocholanolone excretion. Clin. Endocrinol. (Oxf.), 40, 459-64
231. Rittmaster, R. S. (1994). Finasteride. N. Engl. J. Med., 13, 120-5
232. Ciotta, L., Cianci, A., Calogero, A. E., Palumbo, M. A., Marletta, E., Sciuto, A. and Palumbo, G. (1995). Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril., 64, 299-306
233. Wong, I. L., Morris, R. S., Chang, L., Spahan, M. A., Stanczyk, F. Z. and Lobo, R. A. (1995). A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab., 80, 233-8
234. Moghetti, P., Castello, R., Magnani, C. M., Tosi, F., Negri, C., Armanini, D., Bellotti, G. and Mugeo, M. (1994). Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metab., 79, 1115-21
235. Fruzzetti, F., De Lorenzo, D., Parrini, D. and Ricci, C. (1994). Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab., 79, 831-5
236. Levy, M. A., Brandt, M., Dinh, J. T., Holt, D. A., Garrison, L. M., Bergsma, D. J. and Metcalf, B. W. (1994). Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Steroid. Biochem. Mol. Biol., 48, 197-206
237. Giudici, G., Briatico, G., Biagini, L. and Cominato, C. (1994). Effect of 5-reductase inhibitor, turosteride, finasteride and epristeride on prostatic testosterone and dihydrotestosterone in the rat. J. Endocrinol. Invest., 17, P.51
238. Di Salle, E., Briatico, G., Giudici, G., Ornati, G. and Panzeri, A. (1994). Endocrine properties of the 5 alpha-reductase inhibitor turosteride. J. Steroid Biochem. Mol. Biol., 48, 241-8
239. Gjonnaess, H. (1984). Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil. Steril., 41, 20-5
240. Katz, M., Carr, P. J. and Cohen, B. M. (1978). Hormonal effects of wedge resection of polycystic ovaries. Obstet. Gynecol., 51, 437-52
241. Mahesh, V. B., Toledo, S. P. A. and Mattar, E. (1978). Hormonal levels following wedge resection in polycystic ovary syndrome. Obstet. Gynecol., 51, 64-8
242. Judd, H. L., Rigg, L. A. and Anderson, D. C. (1976). The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 43, 347-50
243. Archard, C. and Thiers, J. (1921). Le virilisme pilaire et son association à l'insuffisance glycolytique. Bull. Acad. Nat. Med., 86, 51-5
244. Kahn, C. R., Filier, J. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M. and Roth, J. (1976). The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptors disorders in man. N. Engl. J. Med., 294, 739-45
245. Kahn, C. R., Filier, G. S., Bar, R. S., Archer, J. A., Gorden, P., Martin, M. M. and Roth, J. (1976). The syndromes of insulin resistance and acanthosis nigricans. N. Engl. J. Med., 50, 113-16
246. Rendon, M., Cruz, P. D., Sontheimer, R. D. and Bergstresser, P. R. (1989). Acanthosis nigricans: a cutaneous marker for tissue resistance to insulin. J. Am. Acad. Dermatol., 21, 461
247. Cruz, P. D. and Huld, J. A. (1992). Excess insulin binding insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J. Invest. Dermatol., 98, 825
248. Marcelli, J. M., Debussche, X., Fendri, S., Puy, H. and Arlot, S. (1993). Obésité féminine: la testostéronémie est positivement corrélée à l'insulinorésistance périférique. Ann. Endocrinol. (Paris), 45, 169-73
249. Conway, G. S. and Jacobs, H. S. (1993). Clinical implications of hyperinsulinemia in women. Clin. Endocrinol., 39, 623-32
250. Pedersen, S. B., Borglum, J. D., Schmitz, O., Bak, J. F., Sorensen, N. S. and Richelsen, B. (1993). Abdominal obesity is associated with insulin resistance and reduced glycogen synthase activity in skeletal muscle. Metabolism, 42, 998-1005
251. Conway, G. S., Jacobs, H. S., Holly, G. M. P. and Wass, J. A. S. (1990). Effects of luteinizing hormone, insulin, insulin-like growth factor 1 and insulin-like growth factor small binding protein in the polycystic ovary syndrome. Clin. Endocrinol., 33, 593-603
252. Barbieri, R. L., Makris, A., Randall, R. W., Daniels, G., Kistner, R. W. and Ryan, K. J. (1986). Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab., 62, 904
253. Davoren, J. B., Kasson, B. G., Li, C. H. and Hsueh, A. J. W. (1986). Specific insulin-like growth factor (IGF) I- and II binding sites on rat granulosa cells: relation to IGF action. Endocrinology, 119, 2155
254. Barbieri, R. L., Makris, A. and Ryan, K. (1984). Insulin stimulated androgen accumulation in incubations of human ovarian stroma and theca. Obstet. Gynecol., 64, 73-8
255. Garzo, G. and Dorrington, J. H. (1984). Aromatase activity in human granulosa cells during follicular development and the modulation by follicle-stimulating hormone and insulin. Am. J. Obstet. Gynecol., 148, 657-61
256. Lino, J., Baranao, S. and Hammond, J. M. (1985). Multihormone regulation of steroidogenesis in cultured porcine granulosa cells: studies in serum-free medium. Endocrinology, 116, 2143
257. Zapf, J. and Froesch, E. R. (1986). Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role. Horm. Res., 24, 121
258. Poretsky, L. (1991). On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr. Rev., 12, 3
259. Nestler, J. E., Powers, L. P., Matt, D. W., Steingold, K. A., Plymate, S. R., Rittmaster, R. S., Clore, J. N. and Blackard, W. J. (1991). A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 72, 83
260. Kiddy, D. S., Hamilton-Fairley, D., Seppala, M., Koistinen, R., James, V. H. T., Reed, M. J. and Franks, S. (1989). Diet-induced changes in sex-hormone binding globulin and free testosterone in women with normal and polycystic ovaries: correlation with insulin and insulin-like growth factors-1. Clin. Endocrinol., 31, 757-63
261. Pasupuleti, V. and Horton, R. (1990). Insulin-like growth factor can alter steroid 5-a-reductase activity and formation of dihydrotestosterone in skin. Clin. Res., 38, 99
262. Rosen, O. M. (1989). Structure and function of insulin receptors. Diabetes, 38, 1508
263. Bar, R. S., Harrison, L. C., Muggeo, M., Gorden, P., Kahn, C. R. and Roth, J. (1979). Regulation of insulin receptors in normal and abnormal physiology in humans. Adv. Intern. Med., 24, 23
264. Mosthaf, L., Grako, K., Dull, T. J., Coussens, L., Ullrich, A. and McClain, D. A. (1990). Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J., 9, 2409
265. Geffner, M. E. and Golden, D. W. (1988). Selective insulin action on skin, ovary, and heart in insulin resistant states. Diabetes Care, 11, 500
266. Wagner, R. F. Jr (1990). Physical methods for the management of hirsutism. Cutis, 45, 319
267. Schrioch, E. A. and Schrioch, E. D. (1991). Treatment of hirsutism. Clin. Obstet. Gynecol., 34, 852-63
268. Hinkel, A. R. and Lind, R. W. (1968). Electrolysis, Termolysis and the Blend, pp. 27-35. (California: Arroway Publ.)
269. Ebling, F. J. (1981). In Orfanos, C. E., Montagna, W. and Stuttgen, D. (eds) Hair Research, Status and Future Aspects, pp. 116-30. (Berlin: Springer-Verlag)
270. Prelevic, G. M., Wurzburgher, M. I., Balint-Peric, L. J and Nesic, J. (1990). Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroid in polycystic ovary syndrome. Lancet, 336, 900-3
271. Vos, P., Croughs, R. J. M. and Thijssen, J. H. H. (1988). Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue. Acta Endocrinol., 118, 587-90
272. Koerker, D. T., Ruch, W., Chideckel, E., Palmer, J., Goodner, C. J., Ensick, J. and Gale, C. C. (1974). Somatostatin hypothalamic inhibitor of the endocrine pancreas. Science, 184, 482-4
273. Williams, G., Fuessl, H., Kraenzlin, M. and Bloom, S. R. (1986). Post prandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scand. J. Gastroenterol., 119, 73-83
274. Prelevic, M. G., Ginsburg, J., Maletic, D., Hardiman, P., Okolo, S., Balint-Peric, L., Thomas, M. and Orskov, H. (1995). The effects of somatostatin analogue octreotide on ovulatory performance in women with polycystic ovaries. Hum. Reprod., 10, 28-32
275. Prelevic, M. G., Wurtzburger, M. I., Balint-Peric, L., Hardiman, P., Okolo, S., Maletic, D. and Ginsburg, J. (1992). Effects of somatostatin analogue Octreotide, in polycystic ovary syndrome. Metabolism, 41, 76-9
276. Caron, P. H. (1995). Intramuscular injection of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide. Eur. J. Endocrinol., 132, 320-5
277. Heron, J. and Kuhn, M. (1993). Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab., 76, 721-7